journal
https://read.qxmd.com/read/32988659/reply-to-similar-risk-of-hepatocellular-carcinoma-during-long-term-entecavir-or-tenofovir-therapy-in-caucasian-patients-with-chronic-hepatitis-b
#1
LETTER
George Papatheodoridis, Vana Sypsa, Pietro Lampertico
No abstract text is available yet for this article.
September 25, 2020: Journal of Hepatology
https://read.qxmd.com/read/32988658/benefits-of-molecular-profiling-with-next-generation-sequencing-for-the-diagnosis-and-prognosis-of-myeloproliferative-neoplasms-in-splanchnic-vein-thrombosis
#2
LETTER
Jean-Jacques Kiladjian, Pierre-Edouard Debureaux, Aurélie Plessier, Juliette Soret-Dulphy, Dominique Valla, Bruno Cassinat, Pierre-Emmanuel Rautou
No abstract text is available yet for this article.
September 25, 2020: Journal of Hepatology
https://read.qxmd.com/read/32988657/reply-to-model-for-end-stage-liver-disease-sodium-in-acute-on-chronic-liver-failure
#3
LETTER
Ruben Hernaez, Yan Liu, Fasiha Kanwal
No abstract text is available yet for this article.
September 25, 2020: Journal of Hepatology
https://read.qxmd.com/read/32988656/challenges-in-understanding-the-consequences-of-variants-in-abcb4-gene
#4
LETTER
Jeremy S Nayagam, Sandra Strautnieks, Deepak Joshi, Richard J Thompson
No abstract text is available yet for this article.
September 25, 2020: Journal of Hepatology
https://read.qxmd.com/read/32987030/dicoumarol-an-nqo1-inhibitor-blocks-cccdna-transcription-by-promoting-degradation-of-hbx
#5
Sheng-Tao Cheng, Jie-Li Hu, Ji-Hua Ren, Hai-Bo Yu, Shan Zhong, Vincent Kam Wai Wong, Betty Yuen Kwan Law, Wei-Xian Chen, Hong-Mei Xu, Zhen-Zhen Zhang, Xue-Fei Cai, Yuan Hu, Wen-Lu Zhang, Quan-Xin Long, Fang Ren, Hong-Zhong Zhou, Ai-Long Huang, Juan Chen
BACKGROUND: Current antiviral therapies help keep hepatitis B virus (HBV) under control, but they are not curative. A cure for chronic hepatitis B (CHB) is lacking due to the inability of current therapies to eliminate the intracellular viral replication intermediate termed covalently closed-circular DNA (cccDNA). Therefore, there is an urgent need to develop strategies to cure CHB. Functional silencing of cccDNA is a crucial curative strategy that may be achieved by targeting the viral protein HBx...
September 25, 2020: Journal of Hepatology
https://read.qxmd.com/read/32987029/small-diameter-tips-should-lead-to-safely-expanding-the-use-of-tips
#6
REVIEW
Jaime Bosch
TIPS is increasingly used worldwide in the treatment of complications from of portal hypertension in advanced cirrhosis. However, its use is hampered by the risk of causing hepatic encephalopathy and of worsening liver function. Reported hemodynamic targets for guiding TIPS are too narrow for being achieved in most cases, and perhaps not entirely adequate nowadays since obtained in the pre-covered stent era. We propose that small diameter TIPS - alone or combined to pharmacological therapy or ancillary interventional radiology procedures- may overcome these limitations while maintaining its beneficial effects by itself or by associating simple additional treatments or procedures...
September 25, 2020: Journal of Hepatology
https://read.qxmd.com/read/32987028/cell-autonomous-hepatocyte-specific-gp130-signalling-is-sufficient-to-trigger-a-robust-innate-immune-response-in-mice
#7
Neele Schumacher, Karsten Yan, Monja Gandraß, Miryam Müller, Christoph Krisp, Robert Häsler, Antonella Carambia, Jerzy-Roch Nofer, Joanna P Bernardes, Mouhamad Khouja, Ilka Thomsen, Karel Chalupsky, Julia Bolik, Christoph Hölscher, Thomas Wunderlich, Johannes Herkel, Philip Rosenstiel, Christoph Schramm, Hartmut Schlüter, Thomas Renné, Hans-Willi Mittrücker, Stefan Rose-John, Dirk Schmidt-Arras
BACKGROUND&AIM: IL-6 cytokine family members contribute to inflammatory and regenerative processes. Engagement of the signalling receptor subunit gp130 is common to almost all members of the family. In the liver, all major cell types respond to IL-6, making it difficult to delineate cell type-specific effects of IL-6 type cytokines. We therefore generated mouse models for liver cell type-specific analysis of IL-6 signalling. METHODS: We produced mice with a Cre-inducible expression cassette encoding a designed pre-dimerized constitutive active gp130 variant...
September 25, 2020: Journal of Hepatology
https://read.qxmd.com/read/32981752/reply-to-fib-4-cut-off-should-be-re-evaluated-in-patients-with-metabolic-associated-fatty-liver-disease-mafld
#8
LETTER
Emmanuel A Tsochatzis, Ankur Srivastava, William Rosenberg
No abstract text is available yet for this article.
September 24, 2020: Journal of Hepatology
https://read.qxmd.com/read/32981751/comment-on-next-generation-sequencing-in-the-diagnosis-of-non-cirrhotic-splanchnic-vein-thrombosis
#9
LETTER
Douglas Tremblay, John Mascarenhas, Thomas Schiano, Leonard Naymagon
No abstract text is available yet for this article.
September 24, 2020: Journal of Hepatology
https://read.qxmd.com/read/32976865/cell-therapy-for-advanced-liver-diseases-repair-or-rebuild
#10
REVIEW
Benjamin J Dwyer, Mark T Macmillan, Paul N Brennan, Stuart J Forbes
Advanced liver disease presents a significant worldwide health and economic burden and accounts for 3.5% of global mortality. When liver disease progresses to organ failure the only effective treatment is liver transplantation which requires lifelong immune suppression and brings associated risks. Furthermore, the shortage in suitable donor organs means patients may die waiting for a suitable transplant organ. Cell therapies have made their way from animal studies to a small number of early clinical trials...
September 22, 2020: Journal of Hepatology
https://read.qxmd.com/read/32976864/multicenter-validation-of-the-liver-graft-assessment-following-transplantation-l-graft-score-for-assessment-of-early-allograft-dysfunction
#11
Vatche G Agopian, Daniela Markovic, Goran B Klintmalm, Giovanna Saracino, William C Chapman, Neeta Vachharajani, Sander S Florman, Parissa Tabrizian, Brandy Haydel, David Nasralla, Peter J Friend, Yuri L Boteon, Rutger Ploeg, Michael P Harlander-Locke, Victor Xia, Joseph DiNorcia, Fady M Kaldas, Hasan Yersiz, Douglas G Farmer, Ronald W Busuttil
BACKGROUND AIMS: Early allograft dysfunction (EAD) following liver transplantation (LT) negatively impacts graft and patient outcomes. The Liver Graft Assessment Following Transplantation (L-GrAFT7 ) risk-score estimates 3-month graft-failure-free survival (area under the receiver operator characteristic [AUROC] curve=0.83), and was superior to the binary EAD (AUROC=0.68) definition and Model for Early Allograft Function (MEAF, AUROC=0.70) in the single-center derivation cohort (DC, n=2008)...
September 22, 2020: Journal of Hepatology
https://read.qxmd.com/read/32972731/reply-to-management-of-portopulmonary-hypertension-what-is-more-important-pah-severity-or-liver-disease-severity
#12
LETTER
Laurent Savale, Olivier Sitbon
No abstract text is available yet for this article.
September 21, 2020: Journal of Hepatology
https://read.qxmd.com/read/32972730/validation-of-baveno-vi-and-expanded-baveno-vi-criteria-to-identify-high-risk-varices-in-patients-with-mafld-related-compensated-cirrhosis
#13
LETTER
Kenneth I Zheng, Chuan Liu, Jia Li, Lili Zhao, Ming-Hua Zheng, Fengmei Wang, Xiaolong Qi
No abstract text is available yet for this article.
September 21, 2020: Journal of Hepatology
https://read.qxmd.com/read/32971137/a-global-investment-framework-for-the-elimination-of-hepatitis-b
#14
Jessica Howell, Alisa Pedrana, Sophia E Schroeder, Nick Scott, Lisa Aufegger, Rifat Atun, Ricardo Baptista-Leite, Gottfried Hirnschal, Ellen 't Hoen, Sharon J Hutchinson, Jeffrey V Lazarus, Lesi Olufunmilayo, Raquel Peck, Manik Sharma, Annette H Sohn, Alexander Thompson, Mark Thursz, David Wilson, Margaret Hellard
BACKGROUND AND AIMS: More than 292 million people are living with hepatitis B worldwide and are at risk of death from liver cirrhosis and liver cancer. The World Health Organization (WHO) has set global targets for the elimination of viral hepatitis as a public health threat by 2030. However, current levels of global investment in viral hepatitis elimination programmes are insufficient to achieve these goals. METHODS: To catalyse political commitment and to encourage domestic- and international-financing, we used published modelling data and key stakeholder interviews to develop an investment framework to demonstrate the return on investment for viral hepatitis elimination...
September 21, 2020: Journal of Hepatology
https://read.qxmd.com/read/32962868/cirrhotic-controls-in-a-pooled-analysis-of-hepatitis-d-and-hepatocellular-carcinoma
#15
LETTER
Ilona Argirion, Parag Mahale, Ruth M Pfeiffer, Jill Koshiol, Thomas R O'Brien
No abstract text is available yet for this article.
September 19, 2020: Journal of Hepatology
https://read.qxmd.com/read/32958329/from-pregnant-women-to-infants-non-alcoholic-fatty-liver-disease-is-a-poor-inheritance
#16
LETTER
Antonella Mosca, Nadia Panera, Giuseppe Maggiore, Anna Alisi
No abstract text is available yet for this article.
September 18, 2020: Journal of Hepatology
https://read.qxmd.com/read/32951914/letter-regarding-benchmark-performance-of-laparoscopic-left-lateral-sectionectomy-and-right-hepatectomy-in-expert-centers
#17
LETTER
Brian K P Goh
No abstract text is available yet for this article.
September 17, 2020: Journal of Hepatology
https://read.qxmd.com/read/32951913/reply-to-letter-regarding-benchmark-performance-of-laparoscopic-left-lateral-sectionectomy-and-right-hepatectomy-in-expert-centers
#18
LETTER
Christian Hobeika, David Fuks
No abstract text is available yet for this article.
September 17, 2020: Journal of Hepatology
https://read.qxmd.com/read/32951912/corrigendum-to-genome-wide-and-mendelian-randomisation-studies-of-liver-mri-yield-insights-into-the-pathogenesis-of-steatohepatitis-j-hepatol-2020-241-251
#19
Constantinos A Parisinos, Henry R Wilman, E Louise Thomas, Matt Kelly, Rowan C Nicholls, John McGonigle, Stefan Neubauer, Aroon D Hingorani, Riyaz S Patel, Harry Hemingway, Jimmy D Bell, Rajarshi Banerjee, Hanieh Yaghootkar
No abstract text is available yet for this article.
September 17, 2020: Journal of Hepatology
https://read.qxmd.com/read/32951911/reply-to-errors-in-modeling-misrepresent-the-utility-of-the-enhanced-liver-fibrosis-test-in-the-management-of-non-alcoholic-fatty-liver-disease
#20
LETTER
Yasaman Vali, Quentin M Anstee, Patrick M Bossuyt
No abstract text is available yet for this article.
September 17, 2020: Journal of Hepatology
journal
journal
20153
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"